Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients
Authors: David A. Reardon
James E. Herndon
Katherine Peters
Annick Desjardins
April Coan
Emil Lou
Ashley Sumrall
Scott Turner
Sith Sathornsumetee
Jeremy N. Rich
Susan Boulton
Eric S. Lipp
Henry S. Friedman
James J. Vredenburgh
Dana-Farber Cancer Institute
Duke University School of Medicine
Mahidol University
Cleveland Clinic Foundation
Keywords: Biochemistry, Genetics and Molecular Biology;Medicine;Neuroscience
Issue Date: 1-Mar-2012
Citation: Journal of Neuro-Oncology. Vol.107, No.1 (2012), 213-221
Abstract: Although outcome following bevacizumab among recurrent grade IV malignant glioma patients is documented as poor by several analyses, outcome for recurrent grade III patients following bevacizumab therapy has not been specifically evaluated. We performed a pooled analysis of 96 recurrent grade III malignant glioma patients enrolled on three consecutive phase II bevacizumab salvage trials to evaluate overall outcome following bevacizumab trial discontinuation. Outcome on the three bevacizumab trials, which included similar eligibility, treatment and assessment criteria, was comparable. Fortynine patients who progressed on bevacizumab trial therapy and remained alive for at least 30 days elected to receive additional therapy. These patients achieved a median PFS- 6 and OS of 30.6% (95% CI: 18.4, 43.6) and 10.3 months (95% CI: 5.2, 11.7), respectively. Among patients who continued bevacizumab therapy (n = 23) after study progression, PFS-6 and median OS were 39.1% (95% CI: 19.9, 58.0) and 9.2 months (95% CI: 5.2, 13.6), respectively, compared to 23.1% (95% CI: 9.4, 40.3; P = 0.51) and 10.3 months (95% CI: 2.5, 14.4; P = 0.91) for patients who initiated non-bevacizumab containing therapy (n = 26). Outcome after discontinuation of bevacizumab therapy for recurrent grade III malignant glioma patients is associated with improved outcome compared to historical data for recurrent grade IV malignant glioma patients. Salvage therapies following bevacizumab failure have modest activity for grade III malignant glioma patients that is independent of further bevacizumab continuation. © Springer Science+Business Media, LLC. 2011.
ISSN: 15737373
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.